These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 29880308

  • 1. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, Tessmann EH, Juliusson PB, Skrivarhaug T, Pearson ER, Flanagan SE, Babiker T, Thomas NJ, Shepherd MH, Ellard S, Klimes I, Szopa M, Polak M, Iafusco D, Hattersley AT, Njølstad PR, Neonatal Diabetes International Collaborative Group.
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
    Babiker T, Vedovato N, Patel K, Thomas N, Finn R, Männikkö R, Chakera AJ, Flanagan SE, Shepherd MH, Ellard S, Ashcroft FM, Hattersley AT.
    Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
    [Abstract] [Full Text] [Related]

  • 4. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
    Mancioppi V, Pozzi E, Zanetta S, Missineo A, Savastio S, Barbetti F, Mellone S, Giordano M, Rabbone I.
    Front Endocrinol (Lausanne); 2023 Jun; 14():1143736. PubMed ID: 37251668
    [Abstract] [Full Text] [Related]

  • 5. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT, Neonatal Diabetes International Collaborative Group.
    N Engl J Med; 2006 Aug 03; 355(5):467-77. PubMed ID: 16885550
    [Abstract] [Full Text] [Related]

  • 6. Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes.
    Bowman P, Mathews F, Barbetti F, Shepherd MH, Sanchez J, Piccini B, Beltrand J, Letourneau-Freiberg LR, Polak M, Greeley SAW, Rawlins E, Babiker T, Thomas NJ, De Franco E, Ellard S, Flanagan SE, Hattersley AT, Neonatal Diabetes International Collaborative Group.
    Diabetes Care; 2021 Jan 03; 44(1):35-42. PubMed ID: 33184150
    [Abstract] [Full Text] [Related]

  • 7. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control.
    Stanik J, Dankovcikova A, Barak L, Skopkova M, Palko M, Divinec J, Klimes I, Gasperikova D.
    Diabet Med; 2018 Mar 03; 35(3):386-391. PubMed ID: 29278452
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ.
    Diabetologia; 2006 Nov 03; 49(11):2559-63. PubMed ID: 17047922
    [Abstract] [Full Text] [Related]

  • 10. Hypoglycemia in sulfonylurea-treated KCNJ11-neonatal diabetes: Mild-moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures.
    Lanning MS, Carmody D, Szczerbiński Ł, Letourneau LR, Naylor RN, Greeley SAW.
    Pediatr Diabetes; 2018 May 03; 19(3):393-397. PubMed ID: 29205704
    [Abstract] [Full Text] [Related]

  • 11. Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene.
    Vendramini MF, Gurgel LC, Moisés RS.
    Arq Bras Endocrinol Metabol; 2010 Nov 03; 54(8):682-4. PubMed ID: 21340152
    [Abstract] [Full Text] [Related]

  • 12. Clinical presentation and long-term outcome of patients with KCNJ11/ABCC8 variants: Neonatal diabetes or MODY in the DPV registry from Germany and Austria.
    Warncke K, Eckert A, Kapellen T, Kummer S, Raile K, Dunstheimer D, Grulich-Henn J, Woelfle J, Wenzel S, Hofer SE, Dost A, Holl RW.
    Pediatr Diabetes; 2022 Nov 03; 23(7):999-1008. PubMed ID: 35822653
    [Abstract] [Full Text] [Related]

  • 13. Neonatal diabetes due to potassium channel mutation: Response to sulfonylurea according to the genotype.
    Garcin L, Mericq V, Fauret-Amsellem AL, Cave H, Polak M, Beltrand J.
    Pediatr Diabetes; 2020 Sep 03; 21(6):932-941. PubMed ID: 32418263
    [Abstract] [Full Text] [Related]

  • 14. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
    Tonini G, Bizzarri C, Bonfanti R, Vanelli M, Cerutti F, Faleschini E, Meschi F, Prisco F, Ciacco E, Cappa M, Torelli C, Cauvin V, Tumini S, Iafusco D, Barbetti F, Early-Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology.
    Diabetologia; 2006 Sep 03; 49(9):2210-3. PubMed ID: 16816952
    [No Abstract] [Full Text] [Related]

  • 15. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.
    Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT, Neonatal Diabetes International Collaborative Group.
    Diabetes Care; 2008 Feb 03; 31(2):204-9. PubMed ID: 18025408
    [Abstract] [Full Text] [Related]

  • 16. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.
    Thurber BW, Carmody D, Tadie EC, Pastore AN, Dickens JT, Wroblewski KE, Naylor RN, Philipson LH, Greeley SA, United States Neonatal Diabetes Working Group.
    Diabetologia; 2015 Jul 03; 58(7):1430-5. PubMed ID: 25877689
    [Abstract] [Full Text] [Related]

  • 17. A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications.
    Tammaro P, Flanagan SE, Zadek B, Srinivasan S, Woodhead H, Hameed S, Klimes I, Hattersley AT, Ellard S, Ashcroft FM.
    Diabetologia; 2008 May 03; 51(5):802-10. PubMed ID: 18335204
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up.
    Klupa T, Skupien J, Mirkiewicz-Sieradzka B, Gach A, Noczynska A, Zubkiewicz-Kucharska A, Szalecki M, Kozek E, Nazim J, Mlynarski W, Malecki MT.
    Diabetes Technol Ther; 2010 May 03; 12(5):387-91. PubMed ID: 20184447
    [Abstract] [Full Text] [Related]

  • 19. Neonatal diabetes mellitus due to a new KCNJ11 mutation - 10 years of the patient`s follow-up.
    Ješić MD, Stock H, Zdravković V, Kovačević S, Savić M, Ješić MM.
    Turk J Pediatr; 2021 May 03; 63(3):490-494. PubMed ID: 34254494
    [Abstract] [Full Text] [Related]

  • 20. Detection of KCNJ11 gene mutations in a family with neonatal diabetes mellitus: implications for therapeutic management of family members with long-standing disease.
    Abbasi F, Saba S, Ebrahim-Habibi A, Sayahpour FA, Amiri P, Larijani B, Amoli MM.
    Mol Diagn Ther; 2012 Apr 01; 16(2):109-14. PubMed ID: 22471336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.